Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.3022
https://www.valueinhealthjournal.com/article/S1098-3015(17)33357-0/fulltext
Title :
Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33357-0&doi=10.1016/j.jval.2017.08.3022
First page :
A447
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
256